Medication info
Linagliptin Duo Tablet 2.5/1000 mg (Linagliptin, Metformin)

Linagliptin Duo Tablet 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Pink, oval, film-coated tablet with a double convex shape
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401060 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see “Precautions for Use,” section 3, “Patients Requiring Cautious Administration”). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see “Precautions for Use,” section 3, “Patients Requiring Cautious Administration”). No studies have been conducted to investigate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see “Precautions for Use,” section 2, “Patients Who Must Not Receive This Medicine”).

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes for whom the combination of Linagliptin and Metformin is appropriate. When used in conjunction with diet and exercise, it can facilitate more effective blood sugar management. This medication maintains stable blood sugar levels and also helps prevent complications. With consistent use, positive effects on diabetes treatment can be expected. It is an important treatment that supports the patient's healthy lifestyle.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see “Precautions for Use,” section 3, “Patients Requiring Cautious Administration”). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see “Precautions for Use,” section 3, “Patients Requiring Cautious Administration”). No studies have been conducted to investigate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see “Precautions for Use,” section 2, “Patients Who Must Not Receive This Medicine”).

Precautions

This medication is helpful for controlling blood sugar levels. However, caution must be exercised as serious side effects such as lactic acidosis may occur when taking this medication. Lactic acidosis is a rare condition that occurs when too much lactic acid builds up in the body and can be life-threatening if symptoms are severe. This medication should not be used in patients with certain conditions. For example, patients who are allergic to any of the components of this medication, have type 1 diabetes, severe kidney impairment, liver dysfunction, acute alcohol intoxication, or women who are pregnant or breastfeeding should not take this medication. Additionally, caution is needed when using this medication with other drugs that have a risk of hypoglycemia, as blood sugar can drop too low. In particular, when taken with insulin or sulfonylureas, the dosage should be adjusted according to the physician’s instructions. In situations where renal function may decline, this medication should be temporarily discontinued, and regular monitoring of kidney function is important. For example, this medication should be discontinued in cases of dehydration, severe infection, severe trauma, shock, or before and after the use of radiologic contrast agents. Acute pancreatitis or skin blistering may occur, so if abdominal pain or skin abnormalities occur during treatment, the patient should inform their doctor immediately. This medication may lower vitamin B12 levels, so if taken for an extended period, vitamin B12 deficiency should be periodically checked. Women who are pregnant or planning to become pregnant should avoid taking this medication, and breastfeeding women are also advised against its use. In the elderly, decline in kidney function is common, so while using this medication, kidney function should be regularly monitored, and appropriate dosage adjustments should be made. There may also be interactions with other medications taken concurrently, so if the patient is taking other medications, they must inform their doctor or pharmacist. Lastly, in case of overdose, there is a risk of lactic acidosis and other complications, so the dosage must be strictly adhered to, and in the event of overdose, immediate medical treatment should be sought. This medication is not recommended for children, and its effects on driving or operating machinery are not known. Store it in a place out of reach of children and avoid moisture and direct sunlight.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbances
  • cough
  • decreased appetite
Show 143 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • ileocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplantation failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • dizziness
  • drowsiness
  • chest discomfort
  • weakness
  • epistaxis
  • oropharyngeal pain
  • dysphonia
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • anxiety
  • affective disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • diabetic neuropathy
  • headache
  • sensory abnormalities
  • post-herpetic neuralgia
  • hemiplegia
  • syncope
  • drowsiness
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • benign
  • malignant
  • and unspecified neoplasms
  • myelodysplastic syndrome
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • cavities
  • enteritis
  • gastritis
  • stomatitis
  • increased serum creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • pruritus
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be kept in a tightly closed container. It is advisable to maintain a storage temperature between 1°C and 30°C to ensure the efficacy of the medication.

Appearance and packaging

Appearance

Pink, oval, film-coated tablet with a double convex shape

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.